GZYK(SZ:002524)2026-01-30 09:05Financial Performance - The company expects a net profit in the range of -5,000 to -3,000 thousand yuan, representing a year-on-year increase of 97.14% to 98.28% compared to the previous year's net profit of -17,465.34 thousand yuan[5]. - The net profit after deducting non-recurring gains and losses is projected to be between -18,000 and -12,000 thousand yuan, showing a year-on-year increase of 90.75% to 93.83% from -19,452.68 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.0099 and -0.0050 yuan, compared to -0.34 yuan in the previous year[5]. Operational Management - The company has implemented lean operational management in its medical sector, enhancing operational efficiency through process optimization and cost control measures[7]. - The company anticipates a significant reduction in goodwill impairment compared to 2024, where the impairment provision was 13,463.26 thousand yuan[8]. Earnings Forecast - The financial data presented is preliminary and has not yet been audited by the accounting firm, but there are no significant discrepancies reported[6]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. - The company has communicated with the accounting firm regarding significant matters related to the earnings forecast[6]. Incentive Plan - The company did not meet the performance assessment trigger values for the 2023 restricted stock incentive plan for the year 2025, leading to a reversal of previously accrued share-based payment expenses[7].